Cethromycin - Wikipedia, the free encyclopedia
Cethromycin (initially known as ABT-773 [1] [2]) is a ketolide antibiotic undergoing research for the treatment of community acquired pneumonia (CAP) [1] [3] [4] [5] and for the ...
Ketolide - Wikipedia, the free encyclopedia
The only ketolide on the market at this moment is telithromycin, which is sold under the brand name of Ketek. Another promising ketolide is cethromycin.
Advanced Life Sciences submits NDA for cethromycin in mild-to-moderate ...
Advanced Life Sciences Holdings, Inc. has announced the submission of a new drug application (NDA) for cethromycin in mild-to-moderate community acquired pneumonia (CAP).
Advanced Life Sciences Announces Cethromycin NDA Accepted For Filing ...
Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), announced that the U.S. Food and Drug Administration (FDA) has accepted and filed the Company's New Drug Application (NDA ...
Advanced Life Sciences Announces Successful Thorough QT Study of ...
-Study Results Show Cethromycin Not Associated with QT Prolongation- -Favorable Cardiac Safety Profile Strengthens NDA- CHICAGO, Feb. 19 /PRNewswire-FirstCall ...
BioWorld Today
"So there's a great opportunity for cethromycin to become a front-line" treatment, Flavin added. In Phase III studies, once-daily oral cethromycin proved noninferior to the current ...
Investors Anticipating FDA Approval of Cethromycin :: The OTC Investor ...
Advanced Life Sciences Holdings, Inc. [[ADLS.OB]] may not be the most well known company in the biopharmaceutical space, but the stock’s rapid price movement is catching the ...
Cethromycin achieves all endpoints in second pivotal Phase III Trial ...
Advanced Life Sciences Holdings, Inc. today announced positive results from Trial CL-05, the second of two pivotal phase III clinical trials designed to assess the safety and ...
Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial ...
Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia. - Trial CL-05 Results Showed Cethromycin had 94.0% Clinical Cure Rate Compared ...
Noninferiority Trials
Testimony of James Floyd, M.D., Public Citizen June 2, 2009 Meeting of Anti-Infective Drugs Advisory Committee Cethromycin for the Treatment of Community-Acquired Bacterial ...
Therapeutics Daily
CHICAGO, May 2 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. today announced that its novel respiratory antibiotic, Cethromycin, was shown to be effective in ...
